Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol for Individuals at Risk for Alzheimer's Disease
NCT05822362Phase 2Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Jan 2024
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cannabidiol in Mild Cognitive Impairment (MCI), sponsored by University of Colorado Denver. Started Jan 2024; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT05822362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05822362.